» Articles » PMID: 30504329

Optimizing Quality Care for the Oral Vitamin K Antagonists (VKAs)

Overview
Specialty Hematology
Date 2018 Dec 4
PMID 30504329
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Vitamin K antagonists (VKAs) have been the only oral anticoagulants for decades. The management of anticoagulant therapy with VKA is challenging because of the intricate pharmacological properties of these agents. The success of VKA therapy depends on the quality of treatment that is ensured through continuing comprehensive communication and education. The educational program should address important issues of the VKA therapy such as beginning of treatment, pharmacological, dietary, and drug-drug interactions, as well as treatment temporary suspension during surgical interventions or invasive maneuvers. In addition, the initial and continuing patient education is of imperative importance. A major role in the educational process may be addressed by patient associations. The quality of treatment is better reached if patients are followed in anticoagulation clinics. Moreover, a federation of anticoagulation clinics may improve patient care through regular meetings to update knowledge on VKA treatment. Learning objectives of this paper is to allow readers to correctly approach patients starting VKA treatment, recognize possible pitfalls of treatment, and provide adequate solutions.

Citing Articles

Synergy of Mutation-Induced Effects in Human Vitamin K Epoxide Reductase: Perspectives and Challenges for Allo-Network Modulator Design.

Botnari M, Tchertanov L Int J Mol Sci. 2024; 25(4).

PMID: 38396721 PMC: 10889538. DOI: 10.3390/ijms25042043.


Cost-Utility and Budget Impact Analysis of Implementing Anticoagulation Clinics and Point-of-Care Monitoring Devices in Anticoagulated Patients in Argentina.

Garay O, Guinazu G, Adamczuk Y, Duboscq C Pharmacoecon Open. 2022; 6(5):657-668.

PMID: 35835938 PMC: 9440177. DOI: 10.1007/s41669-022-00352-4.


Efficacy and safety of non-vitamin K antagonist oral anticoagulants for venous thromboembolism: a meta-analysis.

Zhuang Y, Dai L, Chen M JRSM Open. 2021; 12(6):20542704211010686.

PMID: 34178359 PMC: 8207293. DOI: 10.1177/20542704211010686.


Viscoelastometry for detecting oral anticoagulants.

Groene P, Wagner D, Kammerer T, Kellert L, Giebl A, Massberg S Thromb J. 2021; 19(1):18.

PMID: 33726769 PMC: 7962229. DOI: 10.1186/s12959-021-00267-w.

References
1.
Crowther M, Ginsberg J, Kearon C, Harrison L, Johnson J, Massicotte M . A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med. 1999; 159(1):46-8. DOI: 10.1001/archinte.159.1.46. View

2.
Kimmel S, French B, Kasner S, Johnson J, Anderson J, Gage B . A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013; 369(24):2283-93. PMC: 3942158. DOI: 10.1056/NEJMoa1310669. View

3.
Budnitz D, Pollock D, Weidenbach K, Mendelsohn A, Schroeder T, Annest J . National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006; 296(15):1858-66. DOI: 10.1001/jama.296.15.1858. View

4.
Pengo V, Zambon C, Fogar P, Padoan A, Nante G, Pelloso M . A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naïve Patients with Non-Valvular Atrial Fibrillation. PLoS One. 2015; 10(12):e0145318. PMC: 4692529. DOI: 10.1371/journal.pone.0145318. View

5.
Tosetto A, Manotti C, Marongiu F . Center-Related Determinants of VKA Anticoagulation Quality: A Prospective, Multicenter Evaluation. PLoS One. 2015; 10(12):e0144314. PMC: 4670074. DOI: 10.1371/journal.pone.0144314. View